LONDON (Alliance News) - Venn Life Sciences Holdings PLC said Tuesday that it had signed a deal worth over EUR1.4 million to conduct a European wide Phase II study for an undisclosed US based company.
The company said that the deal followed multiple contract signings during the year, and expands its US customer base. It has won business worth a total of EUR8 million in the past six months, including Tuesday's deal.
"The recent project wins demonstrate that our strategy of expanding our core services, our locations and our teams is coming to fruition for us as a company, and for our shareholders and our stakeholders. We now have a solid book of profitable contracts and a healthy pipeline of opportunities, which gives us confidence that we will deliver further growth in 2015," said Chief Executive Tony Richardson in a statement.
Shares in Venn are trading up 7.9% at 20.50 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.